Article By:
The Fly
Friday, December 22, 2017 1:20 PM EDT
Roche announced a definitive agreement to fully acquire Ignyta at a price of $27 per share in an all-cash transaction valued at $1.7B on a fully diluted basis.
In this article: RHHBY Also: RXDX, LOXO, MRTX, EXEL, KPTI, SRRA
